Don P. Le

Array ( [id] => 11756095 [patent_doc_number] => 20170202962 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'COMBINATION OF LENALIDOMIDE AND POLYPEPTIDE CONSTRUCT, AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/420152 [patent_app_country] => US [patent_app_date] => 2017-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 15558 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15420152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866203 [patent_doc_number] => 20170233488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'INTERNALIZING HUMAN MONOCLONAL ANTIBODIES TARGETING PROSTATE CANCER CELLS IN SITU' [patent_app_type] => utility [patent_app_number] => 15/418588 [patent_app_country] => US [patent_app_date] => 2017-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 27293 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15418588 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12606702 [patent_doc_number] => 20180094064 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-05 [patent_title] => AFFINITY MATURED ANTI-CCR4 HUMANIZED MONOCLONAL ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 15/418510 [patent_app_country] => US [patent_app_date] => 2017-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31264 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15418510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13209213 [patent_doc_number] => 10118963 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-06 [patent_title] => Antigen binding proteins that bind PD-L1 [patent_app_type] => utility [patent_app_number] => 15/418514 [patent_app_country] => US [patent_app_date] => 2017-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 19743 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15418514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866213 [patent_doc_number] => 20170233497 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF' [patent_app_type] => utility [patent_app_number] => 15/414122 [patent_app_country] => US [patent_app_date] => 2017-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 64 [patent_figures_cnt] => 64 [patent_no_of_words] => 40522 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15414122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14326591 [patent_doc_number] => 10294299 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-21 [patent_title] => Immunological reagents [patent_app_type] => utility [patent_app_number] => 15/513395 [patent_app_country] => US [patent_app_date] => 2017-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 36 [patent_no_of_words] => 29581 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15513395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11851730 [patent_doc_number] => 20170226222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'BISPECIFIC ANTIBODY' [patent_app_type] => utility [patent_app_number] => 15/409312 [patent_app_country] => US [patent_app_date] => 2017-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 20413 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15409312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14199021 [patent_doc_number] => 10266604 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-23 [patent_title] => CD27L antigen binding proteins [patent_app_type] => utility [patent_app_number] => 15/402478 [patent_app_country] => US [patent_app_date] => 2017-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 36776 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 687 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15402478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13929091 [patent_doc_number] => 20190048061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => ANTI-CD37 CHIMERIC ANTIGEN RECEPTORS AND IMMUNE CELLS EXPRESSING THEM [patent_app_type] => utility [patent_app_number] => 16/068765 [patent_app_country] => US [patent_app_date] => 2017-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19864 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16068765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15664099 [patent_doc_number] => 10596257 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-24 [patent_title] => Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies [patent_app_type] => utility [patent_app_number] => 15/399122 [patent_app_country] => US [patent_app_date] => 2017-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 43 [patent_no_of_words] => 51547 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 337 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15399122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11567440 [patent_doc_number] => 20170106085 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-20 [patent_title] => 'COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND CARFILZOMIB' [patent_app_type] => utility [patent_app_number] => 15/389279 [patent_app_country] => US [patent_app_date] => 2016-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 9332 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15389279 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13618659 [patent_doc_number] => 20180360881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => Compositions and Methods for Treatment of Her2 Positive Metastatic Breast Cancer [patent_app_type] => utility [patent_app_number] => 15/781428 [patent_app_country] => US [patent_app_date] => 2016-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6519 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15781428 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11821871 [patent_doc_number] => 20170210809 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-27 [patent_title] => 'BISPECIFIC BINDING AGENTS TARGETING THE IGF-1R AND ERBB3 PATHWAYS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/371536 [patent_app_country] => US [patent_app_date] => 2016-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 55 [patent_no_of_words] => 27611 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15371536 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11649207 [patent_doc_number] => 20170145104 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-25 [patent_title] => 'ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/369290 [patent_app_country] => US [patent_app_date] => 2016-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 104 [patent_figures_cnt] => 104 [patent_no_of_words] => 89514 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15369290 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14611591 [patent_doc_number] => 10358481 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-23 [patent_title] => Engineered antibody constant domain molecules [patent_app_type] => utility [patent_app_number] => 15/367488 [patent_app_country] => US [patent_app_date] => 2016-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 34 [patent_no_of_words] => 28475 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15367488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11604116 [patent_doc_number] => 20170121417 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-04 [patent_title] => 'Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses' [patent_app_type] => utility [patent_app_number] => 15/366474 [patent_app_country] => US [patent_app_date] => 2016-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 27218 [patent_no_of_claims] => 88 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15366474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866202 [patent_doc_number] => 20170233487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'Anti-Clusterin Antibodies and Antigen Binding Fragments and their Use to Reduce Tumor Volume' [patent_app_type] => utility [patent_app_number] => 15/359963 [patent_app_country] => US [patent_app_date] => 2016-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 29941 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15359963 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17875552 [patent_doc_number] => 11447553 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-20 [patent_title] => FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment [patent_app_type] => utility [patent_app_number] => 15/358756 [patent_app_country] => US [patent_app_date] => 2016-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 32 [patent_no_of_words] => 48745 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 157 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15358756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14454275 [patent_doc_number] => 10323090 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-18 [patent_title] => PD1 and/or LAG3 binders [patent_app_type] => utility [patent_app_number] => 15/353919 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 66 [patent_figures_cnt] => 91 [patent_no_of_words] => 47870 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15353919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17604048 [patent_doc_number] => 11332519 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-17 [patent_title] => Serum albumin binders [patent_app_type] => utility [patent_app_number] => 15/774662 [patent_app_country] => US [patent_app_date] => 2016-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 31 [patent_no_of_words] => 42332 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 191 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15774662 [rel_patent_id] =>[rel_patent_doc_number] =>)